Sphera Funds Management Ltd. Buys Sanofi SA, Biomarin Pharmaceutical Inc, Novartis AG, Sells Gilead Sciences Inc, Celgene Corp, Arqule Inc

• New Purchases: BMRN, NVS, MYL, SWTX, ISEE, KPTI, PTI, BLUE, RARE, NLTX, PRNB, VKTX, PTGX, CYTK, KALV, TEVA, ABEO, ADMA, EOLS, IFRX, ZFGN,
• Added Positions: SNY, ACAD, NVO, VRNT, MRK, XFOR, JNJ, BPMC, AMZN, ALLT, FVRR, DTIL, NVMI, PTLA, MSFT, ALNA, XCUR, YMAB, WIX, NERV, GWPH, HARP,
• Reduced Positions: ARQL, BMY, SRPT, MLNX, ALXN, RCKT, PTCT, ARGX, STOK, CSTE, AXGT, QURE, FSCT, KRYS, FOLD, KRNT, BLCM, PRQR, SEDG, NEOS, AUDC, PANW, ZYME, ASMB, RTRX, ARVN,
• Sold Out: GILD, CELG, NICE, DRNA, URGN, RETA, CHMA, STRO, ITRN, AKRO, CHTR, DK, AVRO, PRVL, ABUS, ERYP, CUE, MRSN, TUFN,

For the details of SPHERA FUNDS MANAGEMENT LTD.'s stock buys and sells, go to https://www.gurufocus.com/guru/sphera+funds+management+ltd./current-portfolio/portfolio

1. SPDR Series Trust S&P Biotech (XBI) - 2,800,000 shares, 22.11% of the total portfolio.
2. iShares Nasdaq Biotechnology Index Fund (IBB) - 1,000,000 shares, 10.01% of the total portfolio.
3. Johnson & Johnson (JNJ) - 438,653 shares, 5.31% of the total portfolio. Shares added by 9.66%
4. Bristol-Myers Squibb Company (BMY) - 915,000 shares, 4.88% of the total portfolio. Shares reduced by 17.56%
5. Sanofi SA (SNY) - 1,140,000 shares, 4.75% of the total portfolio. Shares added by 62.86%

Sphera Funds Management Ltd. initiated holding in Biomarin Pharmaceutical Inc. The purchase prices were between $64.27 and $86.37, with an estimated average price of $75.94. The stock is now traded at around $92.75. The impact to a portfolio due to this purchase was 1.76%. The holding were 251,382 shares as of .

Sphera Funds Management Ltd. initiated holding in Novartis AG. The purchase prices were between $84.35 and $95.37, with an estimated average price of $89.9. The stock is now traded at around $91.57. The impact to a portfolio due to this purchase was 1.57%. The holding were 200,000 shares as of .

Sphera Funds Management Ltd. initiated holding in Mylan NV. The purchase prices were between $17.01 and $20.1, with an estimated average price of $18.63. The stock is now traded at around $20.38. The impact to a portfolio due to this purchase was 0.93%. The holding were 560,000 shares as of .

Sphera Funds Management Ltd. initiated holding in SpringWorks Therapeutics Inc. The purchase prices were between $17.74 and $39.52, with an estimated average price of $23.67. The stock is now traded at around $34.19. The impact to a portfolio due to this purchase was 0.64%. The holding were 200,000 shares as of .

Sphera Funds Management Ltd. initiated holding in IVERIC bio Inc. The purchase prices were between $0.93 and $8.58, with an estimated average price of $3.67. The stock is now traded at around $5.76. The impact to a portfolio due to this purchase was 0.62%. The holding were 868,200 shares as of .

Sphera Funds Management Ltd. initiated holding in Karyopharm Therapeutics Inc. The purchase prices were between $9.57 and $19.67, with an estimated average price of $14.66. The stock is now traded at around $15.14. The impact to a portfolio due to this purchase was 0.53%. The holding were 330,000 shares as of .

Sphera Funds Management Ltd. added to a holding in Sanofi SA by 62.86%. The purchase prices were between $44.25 and $50.86, with an estimated average price of $46.92. The stock is now traded at around $49.90. The impact to a portfolio due to this purchase was 1.83%. The holding were 1,140,000 shares as of .

Sphera Funds Management Ltd. added to a holding in ACADIA Pharmaceuticals Inc by 296.67%. The purchase prices were between $37.4 and $51.4, with an estimated average price of $43.7. The stock is now traded at around $42.78. The impact to a portfolio due to this purchase was 0.95%. The holding were 357,000 shares as of .

Sphera Funds Management Ltd. added to a holding in Novo Nordisk A/S by 42.22%. The purchase prices were between $49.86 and $58.26, with an estimated average price of $55.5. The stock is now traded at around $61.51. The impact to a portfolio due to this purchase was 0.91%. The holding were 640,000 shares as of .

Sphera Funds Management Ltd. added to a holding in Verint Systems Inc by 116.15%. The purchase prices were between $42.59 and $55.36, with an estimated average price of $48.01. The stock is now traded at around $57.70. The impact to a portfolio due to this purchase was 0.72%. The holding were 290,699 shares as of .

Sphera Funds Management Ltd. added to a holding in X4 Pharmaceuticals Inc by 1419.28%. The purchase prices were between $9.93 and $14.33, with an estimated average price of $11.92. The stock is now traded at around $10.80. The impact to a portfolio due to this purchase was 0.6%. The holding were 720,000 shares as of .

Sphera Funds Management Ltd. added to a holding in Blueprint Medicines Corp by 149.41%. The purchase prices were between $66.73 and $82.59, with an estimated average price of $75.07. The stock is now traded at around $62.60. The impact to a portfolio due to this purchase was 0.43%. The holding were 106,000 shares as of .

Sphera Funds Management Ltd. sold out a holding in Gilead Sciences Inc. The sale prices were between $61.62 and $67.78, with an estimated average price of $65.21.

Sphera Funds Management Ltd. sold out a holding in Celgene Corp. The sale prices were between $97.62 and $110.41, with an estimated average price of $105.2.

Sphera Funds Management Ltd. sold out a holding in NICE Ltd. The sale prices were between $141.89 and $159.12, with an estimated average price of $152.81.

Sphera Funds Management Ltd. sold out a holding in Dicerna Pharmaceuticals Inc. The sale prices were between $13.81 and $26.92, with an estimated average price of $20.32.

Sphera Funds Management Ltd. sold out a holding in UroGen Pharma Ltd. The sale prices were between $21.11 and $34.86, with an estimated average price of $27.52.

Sphera Funds Management Ltd. sold out a holding in Reata Pharmaceuticals Inc. The sale prices were between $74.57 and $217.92, with an estimated average price of $184.77.